HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CTFA In Brief: Sassaby

This article was originally published in The Rose Sheet

Executive Summary

Sassaby: Expanding mass market distribution from 9,200 to 15,000 doors by 1998, the company said. Sassaby is completing an agreement to enter CVS and Walgreens, and will expand in Eckerds from a few hundred doors to over a thousand. With the recent integration into the Estee Lauder family, Sassaby said it has become much easier to crack the chain drug circuit. The company is also analyzing its opportunities overseas and is investigating bringing Jane into "value-based economies," such as Eastern Europe and South America. On the product front, Sassaby's focus this fall will be on the face, with color cosmetics sampling and educational pieces. In addition, 16 new nail shades will be added this spring; current leading colors are Shock Value, Rebellious, Electricity, Mega Watt and Voltage...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005194

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel